Cancer diagnosis and side effects of its treatment influence the quality of life to a great extent. Despite progress in the treatment of cancer, patients often experience pain and emotional distress (
1-
3). Therefore, the assessment of quality of life in cancer patients is important issue either during treatment or at post treatment period. Collecting quality of life information in cancer clinical trials or in research settings is a usual practice. Since early 1990’s a number of self-reported questionnaires have been developed to assess the quality of life in cancer patients (
4,
5). These were either general core questionnaires for any cancer patients or for site-specific like lung cancer-specific or breast cancer-specific questionnaires (
6). One of the most popular instruments used with cancer patients is the European Organization for Research and Treatment of Cancer (EORTC QOL-C30) that has received growing attention in research settings, outcome studies, and clinical settings (
7).
The EORTC QLQ-C30 contains 30 questions and covers different aspects of quality of life (
8) including physical, role, emotional, cognitive and social functioning, global quality of life, and measures of symptoms such as fatigue, pain, and nausea/vomiting. QLQ-C30 is the most used quality of life questionnaire for cancer patients worldwide (
9). However, in addition to the generic, cancer-specific, and cancer site-specific instruments, there are several psychological measures such as the hospital anxiety and depression scale (HADS), which are usually used in order to assess psychological well being in cancer patients (
10,
11). The HADS is a screening instrument and measures anxiety (HADS-A) and depression (HADS-D) with cut-off values suggestive of mood disorders (
12,
13).
There were few studies that directly tested the relationship between emotional functioning subscale (EF) of the EORTC QLQ-C30 and the HADS. Skarstein et al. (
14) in a study among Norwegian cancer patients showed that the relationship between EF and depression (HADS-D) was weaker than the anxiety score (HADS-A). They suggested that if psychological distress is the main objective of interest in screening studies among cancer patients, then there might need to use a questionnaire for the assessment of depression. In a validation study, it was indicated that there were significant associations between HADS-A (r = -0.67), HADS-D (r = -0.63), and EF dimension (
15).
Diagnosis and treatment of cancer can be very stressful, therefore, due to the emotional burden among cancer patients, asking them to fill in several different questionnaires in busy oncology settings can impose additional burdens on them. On the other hand, asking many different questions from the patients while they need peace and calm is not ethical behavior. Since cancer patients are at high risk for emotional distress (
16), we could not leave them without careful examination. Thus it is argued that we could use short and relatively comprehensive questionnaires in order to do both careful examinations without imposing extra burdens to them. For instance, if we use the EORTC-QLQ-C30 which includes questions about measures of psychological functioning then there is no need to use the HADS or if we use the HADS there is no need to use a similar questionnaire that measures anxiety and depression.